• Products

    World Bond Fund Monthly Positioning & Outlook

    View Now >

  • Insights

    Human-Centric Investing Podcast

    Listen to Latest Episode >

  • Practice Management

    Applied Insights Team

    Learn More >

  • Resources

    Tax Center

    View Now >

  • About Us

    Human-Centric Investing

    Learn More >

Domestic Equity fund

Hartford Healthcare Fund    Share Class - I (HGHIX)


MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 138, 138, 128 and 103 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 6/30/2021)
138 PRODUCTS
Health Category
Based on Risk-Adjusted Returns

Objective

Seeks long-term capital appreciation.

Overview

A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.


The Health-Care Revolution

The health-care sector is undergoing dramatic changes that will impact everything from the drugs we take to the way patients’ medical records are shared. Aging demographics globally and rising prosperity in emerging-market nations will drive even greater demand for lifesaving drugs, innovative procedures, and disruptive medical technology.

Pipeline to Innovation

With innovation and breakthroughs taking place across the globe, the Fund uses a broadly diversified, global approach that seeks to identify companies with the greatest opportunities in areas including biotechnology, medical technology, health services, and pharmaceuticals.

Backed by Size, Scale, and Experience

Wellington Management, the Fund’s sub-adviser, is one of the largest managers of health care stocks in the world. The portfolio managers on the Fund average 26 years of experience.

Portfolio Management
Senior Managing Director
Global Industry Analyst
21
YRS
MANAGING THIS FUND
23
YRS
AT WELLINGTON MANAGEMENT
34
YRS
EXPERIENCE IN THIS INDUSTRY
Senior Managing Director
Global Industry Analyst
17
YRS
MANAGING THIS FUND
21
YRS
AT WELLINGTON MANAGEMENT
38
YRS
EXPERIENCE IN THIS INDUSTRY
Senior Managing Director
Global Industry Analyst
0
YRS
MANAGING THIS FUND
14
YRS
AT WELLINGTON MANAGEMENT
16
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
0
YRS
MANAGING THIS FUND
6
YRS
AT WELLINGTON MANAGEMENT
14
YRS
EXPERIENCE IN THIS INDUSTRY

The portfolio managers are supported by the full resources of Wellington.

Performance

PERFORMANCE %
 
CUMULATIVE %
(as of 6/30/2021)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 6/30/2021)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare I 8.24 26.88 17.92 15.58 16.39 12.64
Benchmark 11.81 28.88 16.95 14.52 15.91 ---
Morningstar Health Category 7.95 30.16 16.10 15.71 15.27 ---
 
CUMULATIVE %
(as of 6/30/2021)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 6/30/2021)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare I 8.24 26.88 17.92 15.58 16.39 12.64
Benchmark 11.81 28.88 16.95 14.52 15.91 ---
Morningstar Health Category 7.95 30.16 16.10 15.71 15.27 ---

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

SI = Since Inception. Fund Inception: 05/01/2000

Share Class Inception: 8/31/06.
Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses. SI performance is calculated from 5/1/00.

Hartford Healthcare Fund I Share Morningstar Ratings
Morningstar awarded the Fund a
Bronze analyst rating on 10/23/2020
overall
(as of 6/30/2021)
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 138, 138, 128 and 103 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

138 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
3 YEAR
(as of 6/30/2021)
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 138, 138, 128 and 103 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

138 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
5 YEAR
(as of 6/30/2021)
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 138, 138, 128 and 103 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

128 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
10 YEAR
(as of 6/30/2021)
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 138, 138, 128 and 103 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

103 PRODUCTS
|
Health Category
Based on Risk-Adjusted Returns
Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.

Characteristics

FUND ESSENTIALS
Inception Date 05/01/2000
Net Assets $1.7 billion
Total Operating Expenses 0.99%
Morningstar Category Health
Lipper Classification Global Health/Biotechnology Funds
CUSIP 416649887
Fund Number 1309
FUND STATS
# of Holdings
112
% in Equities
96
% in Foreign Equities
18
Beta (3 year)
1.06
R Squared (3 year)
0.88
Standard Deviation
18.20%
Turnover- (6/30/2021)
39%
Active Share
57%
Holdings Characteristics
FUND S&P Composite 1500 Health Care Index
Price/Earnings
35.0x 16.4x
Price/Book
5.9x 5.2x
EPS Growth Rate
14.7% 10.9%
Asset Weighted Market Cap (billions)
$102.2 $158.5
Return on Equity
9.0% 22.9%
Median Market Cap (billions)
$6.5 $6.1
Regional Exposure (%)
North America 81
Emerging Markets 7
United Kingdom 5
Japan 4
Developed EU & Middle East ex UK 3
North America 83
Europe 7
Emerging Markets 5
Japan 4
Middle East/Developed 1
Top Ten Holdings (%)
UnitedHealth Group, Inc. 8.28
Eli Lilly & Co. 5.08
Pfizer, Inc. 5.00
Danaher Corp. 3.51
Bristol-Myers Squibb Co. 3.33
Boston Scientific Corp. 3.09
Abbott Laboratories 2.85
AstraZeneca plc 2.68
Edwards Lifesciences Corp. 2.68
Illumina, Inc. 2.33
Total Portfolio % 38.83
UnitedHealth Group, Inc. 8.47
Eli Lilly & Co. 5.14
Pfizer, Inc. 5.10
Thermo Fisher Scientific, Inc. 3.98
Bristol-Myers Squibb Co. 3.36
Abbott Laboratories 3.25
Danaher Corp. 3.24
Boston Scientific Corp. 3.05
AstraZeneca plc 2.45
Edwards Lifesciences Corp. 2.38
Total Portfolio % 40.42
Market Cap Distribution (%)

Market Cap Header

Market Cap Header3

Less than $2 billion 7
$2 billion - $5 billion 9
$5 billion - $10 billion 9
Greater than $10 billion 74
Not Classified 0
RETURN CHARACTERISTICS
Alpha (5 Year)
0.39
Down Capture (5 Year)
103.60
Information Ratio (5 Year)
0.18
Sharpe Ratio (5 Year)
0.91
Up Capture (5 Year)
105.32
Subsector Exposure
Medical Technology 32
Biopharma Large Cap 25
Health Care Services 21
Biopharma Mid Cap 14
Biopharma Small Cap 7
Medical Technology 33
Biopharma Large Cap 23
Health Care Services 22
Biopharma Mid Cap 14
Biopharma Small Cap 8
Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
distributions and capital gains
Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
12/30/2020 43.77 $0.0000 $0.0000 $0.0000 $0.0000
12/11/2020 43.34 $0.0000 $0.7605 $4.4055 $5.1660
Past distributions are not indicative of future distributions.

Fund Literature


07/23/2021 - PDF (205 KB)
This client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance
06/30/2021 - PDF (169 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
03/31/2021 - PDF (457 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
PDF (154 KB)
A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
06/30/2021 - PDF (310 KB)
This Pitchbook reviews the Funds' investment approach, investment team, investment process, and general portfolio parameters.
PDF (3 KB)
An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
PDF (13 KB)
A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
PDF (3 KB)
An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
Morningstar analyst's take on the Hartford Healthcare Fund, which was awarded a Bronze Analyst Rating.
PDF (13 KB)
A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.

 

224648

The material on this site is for informational and educational purposes only. The material should not be considered tax or legal advice and is not to be relied on as a forecast. The material is also not a recommendation or advice regarding any particular security, strategy or product. Hartford Funds does not represent that any products or strategies discussed are appropriate for any particular investor so investors should seek their own professional advice before investing. Hartford Funds does not serve as a fiduciary. Content is current as of the publication date or date indicated, and may be superseded by subsequent market and economic conditions.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the mutual fund, ETF or closed-end interval fund prospectus or summary prospectus, which can be obtained from a financial professional and should be read carefully before investing.

Mutual funds and the closed-end interval fund are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA/SIPC. Exchange-traded products are distributed by ALPS Distributors, Inc. (ALPS). Advisory services may be provided by Hartford Funds Management Company, LLC (HFMC) or its wholly owned subsidiary, Lattice Strategies LLC (Lattice). Certain funds are sub-advised by Wellington Management Company LLP and/or Schroder Investment Management North America Inc. Schroder Investment Management North America Ltd. serves as a secondary sub-adviser to certain funds. Hartford Funds refers to Hartford Funds Management Group, Inc. and its subsidiaries, including HFD, HFMC, and Lattice, which are not affiliated with any sub-adviser or ALPS. The funds and other products referred to on this Site may be offered and sold only to persons in the United States and its territories.

© Copyright 2021 Hartford Funds Management Group, Inc. All Rights Reserved. Not FDIC Insured | No Bank Guarantee | May Lose Value